{"id":"belimumab-gsk1550188","safety":{"commonSideEffects":[{"rate":null,"effect":"Infection (including serious infections)"},{"rate":null,"effect":"Nasopharyngitis"},{"rate":null,"effect":"Bronchitis"},{"rate":null,"effect":"Diarrhea"},{"rate":null,"effect":"Nausea"},{"rate":null,"effect":"Pyrexia"},{"rate":null,"effect":"Infusion reactions"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"Belimumab binds to soluble BLyS (also known as BAFF), a cytokine essential for B cell survival and differentiation. By neutralizing BLyS, the drug reduces the survival of autoreactive B cells and plasma cells, thereby decreasing pathogenic autoantibody levels and immune complex formation. This mechanism addresses a key driver of lupus pathogenesis.","oneSentence":"Belimumab is a monoclonal antibody that inhibits B-lymphocyte stimulator (BLyS), reducing B cell proliferation and autoantibody production in systemic lupus erythematosus.","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T00:28:16.915Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Systemic lupus erythematosus (SLE) with active disease"},{"name":"Lupus nephritis"}]},"trialDetails":[{"nctId":"NCT06572384","phase":"PHASE3","title":"A Study of the Efficacy and Safety of Belimumab in Adults With Interstitial Lung Disease Associated With Connective Tissue Disease","status":"RECRUITING","sponsor":"GlaxoSmithKline","startDate":"2024-09-11","conditions":"Lung Diseases, Interstitial","enrollment":440},{"nctId":"NCT05878717","phase":"PHASE2, PHASE3","title":"A Study of the Efficacy and Safety of Belimumab in Adults With Systemic Sclerosis Associated Interstitial Lung Disease","status":"RECRUITING","sponsor":"GlaxoSmithKline","startDate":"2023-09-13","conditions":"Systemic Sclerosis Associated Interstitial Lung Disease, Scleroderma, Systemic","enrollment":300},{"nctId":"NCT06411249","phase":"PHASE4","title":"A Study Describing the Efficacy and Safety of Belimumab Administered in Adult Participants With Early Systemic Lupus Erythematosus (SLE)","status":"RECRUITING","sponsor":"GlaxoSmithKline","startDate":"2024-06-06","conditions":"Systemic Lupus Erythematosus","enrollment":350},{"nctId":"NCT02631538","phase":"PHASE2","title":"Safety and Efficacy Study of Subcutaneous Belimumab and Intravenous Rituximab Co-administration in Subjects With Primary Sjogren's Syndrome","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2016-02-17","conditions":"Sjogren's Syndrome","enrollment":86},{"nctId":"NCT02880852","phase":"PHASE1","title":"Belimumab Phase I Study in Chinese Subjects With Systemic Lupus Erythematosus","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2017-01-23","conditions":"Systemic Lupus Erythematosus","enrollment":20},{"nctId":"NCT01345253","phase":"PHASE3","title":"GSK1550188 A 52 Week Study of Belimumab Versus Placebo in the Treatment of Subjects With Systemic Lupus Erythematosus (SLE) Located in Northeast Asia","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2011-05-23","conditions":"Systemic Lupus Erythematosus","enrollment":709},{"nctId":"NCT03125486","phase":"","title":"Compassionate Use for Subcutaneous (SC) Belimumab","status":"NO_LONGER_AVAILABLE","sponsor":"GlaxoSmithKline","startDate":"","conditions":"Systemic Lupus Erythematosus","enrollment":""},{"nctId":"NCT01610492","phase":"PHASE2","title":"A Study of Belimumab in Idiopathic Membranous Glomerulonephropathy","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2012-07-01","conditions":"Glomerulonephritis, Membranous","enrollment":14},{"nctId":"NCT01516450","phase":"PHASE1","title":"Japanese phase1 Study of Belimumab (IV vs SC)","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2011-12-26","conditions":"Systemic Lupus Erythematosus","enrollment":16},{"nctId":"NCT01381536","phase":"PHASE1","title":"Phase I Study of GSK1550188 in Japanese Subjects With Systemic Lupus Erythematosus (SLE)","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2010-07-20","conditions":"Systemic Lupus Erythematosus","enrollment":12},{"nctId":"NCT01762852","phase":"PHASE2","title":"Efficacy and Safety Study of Intravenous Belimumab Versus Placebo in Subjects With Idiopathic Membranous Nephropathy","status":"WITHDRAWN","sponsor":"GlaxoSmithKline","startDate":"2013-04","conditions":"Glomerulonephritis, Membranous","enrollment":""}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":0,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":["BEL (BENLYSTA)"],"phase":"marketed","status":"active","brandName":"Belimumab (GSK1550188)","genericName":"Belimumab (GSK1550188)","companyName":"GlaxoSmithKline","companyId":"gsk","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Belimumab is a monoclonal antibody that inhibits B-lymphocyte stimulator (BLyS), reducing B cell proliferation and autoantibody production in systemic lupus erythematosus. Used for Systemic lupus erythematosus (SLE) with active disease, Lupus nephritis.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}